In 2015, Rodney Cummins was a 49-year-old husband and father experiencing multiple symptoms of colorectal cancer (CRC). Less than a year later, he left behind a widow and a broken-hearted daughter.
BlueHQ is the Colorectal Cancer Alliance’s new patient and caregiver support hub. BlueHQ makes it easy to find personalized support, without endless online searching.
A study out of Oslo, Norway, published in the New England Journal of Medicine questioned the effectiveness of colonoscopy in preventing colorectal cancer, the second deadliest cancer in the United States. The study triggered a swell of media reports casting doubt on the procedure.
The questions around implicit bias began to paralyze my voice, but I didn’t let them. I was not going to be someone who idly stood by. I was going to be part of the change.
Earlier this year, six allies traveled to the media capital of the world to share their stories on camera. They were the first allies featured as part of the Colorectal Cancer Alliance’s Living Legacy Program.
Black Americans are 20% more likely than their non-Hispanic white counterparts to be diagnosed with colorectal cancer and 35% more likely to die from it.
We strongly encourage voters to contact the candidates in both parties and request information on their plans to improve access to healthcare and lower costs.
The U.S. Food and Drug Administration has approved encorafenib (marketed as BRAFTOVI) in combination with cetuximab (marketed as ERBITUX) as a second-line therapy for the treatment of adult patients with metastatic colorectal cancer with a BRAFV600E mutation.
Finding out you or a loved one has colorectal cancer can be overwhelming. While standard treatments like surgery, chemotherapy, and radiation remain the cornerstone of cancer care, many patients are exploring supportive therapies to enhance their overall quality of life.